aap receives US-American clearance (FDA) for polyaxial LOQTEQ® VA Elbow system; launch planned for Q4 2023
EQS-News: aap Implantate AG
/ Key word(s): Regulatory Approval/Market Launch
aap Implantate AG (“aap”) announces that its new system LOQTEQ® VA Elbow 2.7/3.5 has been cleared by the US-American Food and Drug Administration (FDA). The Company plans to launch the system LOQTEQ® VA Elbow 2.7/3.5 in the fourth quarter of 2023 in the United States and in other markets that accept FDA clearances. The system enables flexible treatment of fractures of the distal humerus and olecranon important to the elbow function and stability. The LOQTEQ® VA Elbow plates 2.7/3.5 belong to the LOQTEQ® VA (VA = Variable Angle) product family. These are polyaxial implants that facilitate inserting angle-stable screws at different angles, thereby improving flexibility within the application.
With its new distal humerus and olecranon system, aap addresses the upper extremity segment, which accounts for approx. 34% of trauma surgeries. The treatment of distal humeral fractures remains a challenge in trauma surgery. The incidence rates range up to 7% of all fractures and 30% of elbow fractures. The distal humerus holds great importance in the mobility and function for the elbow, requiring innovative fixation solutions to support effective surgical treatment. To meet patients’ growing demands, a swift and stable treatment is required that enables an early restoration of mobility. The system LOQTEQ® VA Elbow 2.7/3.5 comprises a variety of plate solutions for the distal humerus, enabling 90°and 180° treatment options, as well as solution for the olecranon. The anatomical plate design in conjunction with excellent plate-screw connection, choice of screw angles, as well as the incorporated locking and compression technology (LOQTEQ®) in the shaft area, are just a few of the main features incorporated in the system, contributing to great surgical outcome and high comfort of patients.
With the LOQTEQ® VA Elbow 2.7/3.5 aap takes a further important step on the way to the completion of its portfolio in the polyaxial range. In addition, it is coming one step closer in offering an attractive range of products for its antibacterial silver treated solution, currently in human clinical trial phase.
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German Stock Exchanges -
About aap Implantate AG
 Source: Global Trauma Fixation Device Market Insights, Forecast to 2025, page 16; released by QYResearch
 Source: https://www.orthobullets.com/trauma/1017/distal-humerus-fractures, viewed 19.03.2023
aap Implantate AG; Marek Hahn; Member of the Management Board/ CFO; Lorenzweg 5; 12099 Berlin
Tel.: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: firstname.lastname@example.org
21.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1587437|
|End of News||EQS News Service|